All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells

Arisi,Maria F.; Starker,Rebecca A.; Addya,Sankar; Huang,Yong; Fernandez,Sandra V.

doi:10.3892/ijo.2014.2354

All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells

Authors:
- Maria F. Arisi
- Rebecca A. Starker
- Sankar Addya
- Yong Huang
- Sandra V. Fernandez
View Affiliations

Affiliations: Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA, Section of Gastroenterology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
Published online on: March 21, 2014 https://doi.org/10.3892/ijo.2014.2354
Pages: 1831-1842
Copyright: © Arisi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoids have been used as potential chemotherapeutic or chemopreventive agents because of their differentiative, anti-proliferative, pro-apoptotic and antioxidant properties. We investigated the effect of all trans-retinoic acid (ATRA) at different stages of the neoplastic transformation using an in vitro model of breast cancer progression. This model was previously developed by treating the MCF-10F human normal breast epithelial cells with high dose of estradiol and consists of four cell lines which show a progressive neoplastic transformation: MCF-10F, normal stage; trMCF, transformed MCF-10F; bsMCF, invasive stage; and caMCF, tumorigenic stage. In 3D cultures, MCF-10F cells form tubules resembling the structures in the normal mammary gland. After treatment with estradiol, these cells formed tubules and spherical masses which are indicative of transformation. Cells that only formed spherical masses in collagen were isolated (trMCF clone 11) and treated with ATRA. After treatment with 10 or 1 µM ATRA, the trMCF clone 11 cells showed tubules in collagen; 10 and 43% of the structures were tubules in cells treated with 10 and 1 µM ATRA, respectively. Gene expression studies showed that 207 genes upregulated in transformed trMCF clone 11 cells were downregulated after 1 µM ATRA treatment to levels comparable to those found in the normal breast epithelial cells MCF-10F. Furthermore, 236 genes that were downregulated in trMCF clone 11 were upregulated after 1 µM ATRA treatment to similar levels shown in normal epithelial cells. These 443 genes defined a signature of the ATRA re-programming effect. Our results showed that 1 µM ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process and antagonistically regulate breast cancer associated genes. The invasive and tumorigenic cells did not show any changes in morphology after ATRA treatment. These results suggest that ATRA could be used as a chemopreventive agent to inhibit the progression of premalignant lesions of the breast.

View Figures

View References

1.	Theodosiou M, Laudet V and Schubert M: From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci. 67:1423–1445. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Duester G: Retinoic acid synthesis and signaling during early organogenesis. Cell. 134:921–931. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Mongan NP and Gudas LJ: Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation. 75:853–870. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Connolly R, Nguyen NK and Sukumar S: Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 19:1651–1659. 2013. View Article : Google Scholar : PubMed/NCBI
5.	Bushue N and Wan YJ: Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 62:1285–1298. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Aagaard MM, Siersbaek R and Mandrup S: Molecular basis for gene-specific transactivation by nuclear receptors. Biochim Biophys Acta. 1812.824–835. 2011.PubMed/NCBI
7.	Tsai MJ and O’Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 63:451–486. 1994. View Article : Google Scholar : PubMed/NCBI
8.	Rochette-Egly C and Germain P: Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal. 7:e0052009.PubMed/NCBI
9.	Heyman RA, Mangelsdorf DJ, Dyck JA, et al: 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 68:397–406. 1992. View Article : Google Scholar : PubMed/NCBI
10.	Garattini E, Gianni M and Terao M: Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam Horm. 75:301–354. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M and Decensi A: Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. 13:51–68. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Seewaldt VL, Johnson BS, Parker MB, Collins SJ and Swisshelm K: Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 6:1077–1088. 1995.PubMed/NCBI
13.	Swisshelm K, Ryan K, Lee X, Tsou HC, Peacocke M and Sager R: Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 5:133–141. 1994.PubMed/NCBI
14.	Widschwendter M, Berger J, Muller HM, Zeimet AG and Marth C: Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia. 6:193–201. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Russo J, Fernandez SV, Russo PA, et al: 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J. 20:1622–1634. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Huang Y, Fernandez SV, Goodwin S, et al: Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. Cancer Res. 67:11147–11157. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Fernandez SV and Russo J: Estrogen and xenoestrogens in breast cancer. Toxicol Pathol. 38:110–122. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Hebner C, Weaver VM and Debnath J: Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Annu Rev Pathol. 3:313–339. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Snider KE, Ehya H, Russo J and Fernandez SV: NRG1 and RARB hypermethylation in breast cancer progression. In: Proceedings of the ACCR 102nd Anual Meeting; Orlando, FL.. Cancer Res. 71(Suppl 1): abs. 75. pp. 2011
20.	Glass CK and Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121–141. 2000.PubMed/NCBI
21.	Hartman HB, Yu J, Alenghat T, Ishizuka T and Lazar MA: The histone-binding code of nuclear receptor co-repressors matches the substrate specificity of histone deacetylase 3. EMBO Rep. 6:445–451. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Lefebvre B, Ozato K and Lefebvre P: Phosphorylation of histone H3 is functionally linked to retinoic acid receptor beta promoter activation. EMBO Rep. 3:335–340. 2002. View Article : Google Scholar : PubMed/NCBI
23.	McKenna NJ and O’Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 108:465–474. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Rochette-Egly C: Dynamic combinatorial networks in nuclear receptor-mediated transcription. J Biol Chem. 280:32565–32568. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Chen H, Lin RJ, Xie W, Wilpitz D and Evans RM: Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell. 98:675–686. 1999. View Article : Google Scholar : PubMed/NCBI
26.	Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW Jr and Nakshatri H: Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep. 3:25302013. View Article : Google Scholar : PubMed/NCBI
27.	Gudas LJ: Retinoids induce stem cell differentiation via epigenetic changes. Semin Cell Dev Biol. 24:701–705. 2013. View Article : Google Scholar : PubMed/NCBI
28.	Zhang XK, Liu Y and Lee MO: Retinoid receptors in human lung cancer and breast cancer. Mutat Res. 350:267–277. 1996. View Article : Google Scholar : PubMed/NCBI
29.	Hua S, Kittler R and White KP: Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 137:1259–1271. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Soprano DR and Soprano KJ: Pharmacological doses of some synthetic retinoids can modulate both the aryl hydrocarbon receptor and retinoid receptor pathways. J Nutr. 133:277S–281S. 2003.PubMed/NCBI
31.	Murphy KA, Quadro L and White LA: The intersection between the aryl hydrocarbon receptor (AhR)- and retinoic acid-signaling pathways. Vitam Horm. 75:33–67. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Hail N Jr, Kim HJ and Lotan R: Mechanisms of fenretinide-induced apoptosis. Apoptosis. 11:1677–1694. 2006. View Article : Google Scholar
33.	McCormick DL, Becci PJ and Moon RC: Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride-divinyl ether copolymer (MVE-2). Carcinogenesis. 3:1473–1476. 1982. View Article : Google Scholar
34.	McCormick DL and Moon RC: Antipromotional activity of dietary N-(4-hydroxyphenyl)retinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice. Cancer Lett. 31:133–138. 1986. View Article : Google Scholar : PubMed/NCBI
35.	Moon RC, Pritchard JF, Mehta RG, Nomides CT, Thomas CF and Dinger NM: Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis. 10:1645–1649. 1989. View Article : Google Scholar : PubMed/NCBI
36.	Pollard M, Luckert PH and Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res. 51:3610–3611. 1991.PubMed/NCBI